Philips receives FDA approval for AlluraClarity

Philips has received a positive US regulatory decision on AlluraClarity, its innovative interventional X-ray system.

The Food and Drug Administration (FDA) has cleared the live image guidance system for use in the US, following its commercial introduction in international territories in mid-2012.

It offers high-quality imaging for a comprehensive range of clinical procedures and provides excellent visibility for patients of all sizes, while its low X-ray dose levels help clinicians to manage radiation exposure.

More than 200 AlluraClarity systems have been ordered since its debut last year, with this FDA approval meaning the system can now be sold in the world's largest healthcare market.

Gene Saragnese, chief executive of Philips' imaging systems division, said: "The transition from highly-invasive surgical procedures to minimally-invasive image-guided therapies, with all their intrinsic patient benefits, is a transformation in the delivery of healthcare that is rapidly accelerating around the globe."

Earlier this year, the firm also reported success from its ongoing efforts to enhance the sustainability performance of its healthcare offerings as part of a wider environmental strategy.